Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;93(1):74-82.
doi: 10.1007/s12185-010-0750-2. Epub 2011 Jan 5.

Telomeres and prognosis in patients with chronic lymphocytic leukaemia

Affiliations

Telomeres and prognosis in patients with chronic lymphocytic leukaemia

Ludger Sellmann et al. Int J Hematol. 2011 Jan.

Abstract

In the present study, telomere length, telomerase activity, the mutation load of immunoglobulin variable heavy chain (IGHV) genes, and established prognostic factors were investigated in 78 patients with chronic lymphocytic leukaemia (CLL) to determine the impact of telomere biology on the pathogenesis of CLL. Telomere length was measured by an automated multi-colour flow-FISH, and an age-independent delta telomere length (ΔTL) was calculated. CLL with unmutated IGHV genes was associated with shorter telomeres (p = 0.002). Furthermore, we observed a linear correlation between the frequency of IGHV gene mutations and elongation of telomeres (r = 0.509, p < 0.001). With respect to prognosis, a threshold ΔTL of -4.2 kb was the best predictor for progression-free and overall survival. ΔTL was not significantly altered over time or with therapy. The correlation between the mutational load in IGHV genes and the ΔTL in CLL might reflect the initial telomere length of the putative cell of origin (pre- versus post-germinal center B cells). In conclusion, the ΔTL is a reliable prognostic marker for patients with CLL. Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors.

PubMed Disclaimer

References

    1. Eur J Haematol. 2007 Apr;78(4):283-9 - PubMed
    1. Blood. 1999 Sep 15;94(6):1840-7 - PubMed
    1. J Clin Invest. 1997 Oct 1;100(7):1667-76 - PubMed
    1. Blood. 2008 Feb 15;111(4):2388-91 - PubMed
    1. Blood. 2006 Feb 1;107(3):859-61 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources